Jie Yu

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 3

Top Topics

Childhood Cancer

Human Immunodeficiency Virus

Top Venues

Science advances

Nature communications

Takeda Oncology

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Takeda Oncology

United States

Scientist :: I-O Biology

Publications

Tomoko Yamamori Morita, Jie Yu, Yukie Kashima, Ryo Kamata, Gaku Yamamoto, Tatsunori Minamide, Chiaki Mashima, Miyuki Yoshiya, Yuta Sakae, Toyohiro Yamauchi, Yumi Hakozaki, Shun-Ichiro Kageyama, Akito Nakamura, Eric S Lightcap, Kosuke Tanaka, Huifeng Niu, Karuppiah Kannan, Akihiro Ohashi
CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade. Nature communications 14 (1) (2023)
Kenichi Iwai, Tadahiro Nambu, Yukie Kashima, Jie Yu, Kurt Y Eng, Kazumasa Miyamoto, Kazuyo Kakoi, Masamitsu Gotou, Toshiyuki Takeuchi, Akifumi Kogame, Jessica Sappal, Saomi Murai, Hiroshi Haeno, Shun-Ichiro Kageyama, Osamu Kurasawa, Huifeng Niu, Karuppiah Kannan, Akihiro Ohashi
A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery. Science advances 7 (21) (2021)
Kenichi Iwai, Tadahiro Nambu, Ryo Dairiki, Momoko Ohori, Jie Yu, Kristine Burke, Masamitsu Gotou, Yukiko Yamamoto, Shunsuke Ebara, Sachio Shibata, Ryosuke Hibino, Satoru Nishizawa, Tohru Miyazaki, Misaki Homma, Yuya Oguro, Takashi Imada, Nobuo Cho, Noriko Uchiyama, Akifumi Kogame, Toshiyuki Takeuchi, Osamu Kurasawa, Kazunori Yamanaka, Huifeng Niu, Akihiro Ohashi
Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor. Science advances 5 (5) (2019)